ReviewNeuro-oncology practice2021
Late effects of cancer treatment: consequences for long-term brain cancer survivors.
Review in Neuro-oncology practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Pooled it
- Trial
- Biomimetic model for the identification of distinctive microenvironmental factors in glioblastoma radiosensitivity.Clinical and translational radiation oncology · 2026Article
- Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial.Nature medicine · 2026Article
- Cumulative dose of chemotherapy and survival outcomes in children with average-risk medulloblastoma treated on Children's Oncology Group study ACNS0331.Neuro-oncology · 2026Article
- Risk factors and long-term outcomes in smart syndrome: a multicenter study.Journal of neuro-oncology · 2026Article
- Proton versus photon radiotherapy in adults with primary brain tumors evaluating functional survival: a phase 3 randomized controlled trial study protocol (PRIDE).Radiation oncology (London, England) · 2026Article
- Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism.Molecular oncology · 2026Article
- Developmental Foundations of Psychosocial Interventions in Pediatric Oncology: A Lifespan Framework for Resilience.Children (Basel, Switzerland) · 2026Review
- Disability pension receipt five years after cancer diagnosis: a matched registry study of working-age cancer survivors in Norway.Frontiers in health services · 2026Article
- Reassessing the Management of Treatment-Induced Brain Necrosis in Metastatic Patients: Advancing Surgical Alternatives to Steroid Therapy.Neurosurgery practice · 2025Review
- Neurocognitive and Emotional Outcomes in Childhood Cancer: A Developmental Perspective.Current oncology (Toronto, Ont.) · 2025Review
- Impact of partial substitution of cisplatin with cyclophosphamide on acute toxicities in standard-risk medulloblastoma.Journal of neuro-oncology · 2025Article
- Exploring the Role of ADCs in Brain Metastases and Primary Brain Tumors: Insight and Future Directions.Cancers · 2025Review
- Illuminating the hidden cost: A systematic review of cognitive late effects regarding cancer-related fatigue in treated paediatric brain tumors.Technical innovations & patient support in radiation oncology · 2025Review
- Adverse health outcomes and health-related quality of life (HRQoL) among long-term adolescent and young adult (AYA) brain tumour survivors: results from the population-based SURVAYA study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Dexamethasone in brain tumor patients: a real-world pharmacovigilance audit.Frontiers in neurology · 2025Article
- Role and mechanisms of exercise therapy in enhancing drug treatment for glioma: a review.Frontiers in immunology · 2025Review
- Early characterization and prediction of glioblastoma and brain metastasis treatment efficacy using medical imaging-based radiomics and artificial intelligence algorithms.Frontiers in oncology · 2025Review
- Symptom experience and symptom distress in patients with malignant brain tumor treated with proton therapy: A five-year follow-up study.Technical innovations & patient support in radiation oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Late adverse effects of cancer treatments represent a significant source of morbidity and also financial hardship among brain tumor patients. These effects can be produced by direct neurologic damage of the tumor and its removal, and/or by complementary treatments such as chemotherapy and radiotherapy, either alone or combined. Notably, young adults are the critical population that faces major consequences because the early onset of the disease may affect their development and socioeconomic status. The spectrum of these late adverse effects is large and involves multiple domains. In this review we classify the main long-term adverse effects into 4 sections: CNS complications, peripheral nervous system complications, secondary neoplasms, and Economic impact. In addition, CNS main complications are divided into nonfocal and focal symptoms. Owing to all the secondary effects mentioned, it is essential for physicians to have a high level of clinical suspicion to prevent and provide early intervention to minimize their impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.